Cells in the eyes produce a protein known as VEGF. If the eye cells produce too much of this protein, abnormal blood vessels can grow, leading to vision damage and even vision loss. Anti-VEGF treatment is a medication that counteracts the production of the protein, stopping damage and slowing vision loss. Anti-VEGF injections are administered into the eye by an ophthalmologist and are known as intravitreal injections.

Anti-VEGF real-world data includes patients treated for conditions including age-related macular degeneration, diabetic retinopathy, and other ophthalmic conditions.

The use of real-world data from anti-VEGF treatments in Qdata Anti-VEGF Market Tracker can help life sciences companies better actively and accurately track real-world usage of Anti-VEGF in patients with retinal clinicians. Commercialization teams can track rolling market share, brand usage and brand switching by indication.

As an exclusive analytics and real-world data curation partner with the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight), Verana Health’s Qdata Anti-VEGF Market Tracker can provide valuable data pertaining to real-world usage of this treatment.